Services/ Pipelines & Platforms
HoneyBear Biosciences, Inc is a Taiwan-based biotech company with a vision for global pharmaceutical market. We strive to develop new antibody technologies to bring novel antibody-drug conjugates (ADC) to the patients suffering from devastating cancers. HoneyBear Biosciences offers a novel site-specific conjugation and precise DAR control through facile glycan modifications. Our technology allows orthogonal conjugation of two or more different payloads with pre-determined DAR of each payloads.
HoneyBear Biosciences has developed a unique site-specific conjugation platform “Co-Nectar” and a next generation ADC/ARC product pipeline.
Business Interests
In-Licensing, Out-Licensing, Collaborative R&D, CRO, Clinical Trial Collaboration, Distribution, Co-Development, Strategic Alliance
Contact Info
Laura Pang
Administrative Specialist
+886-2-26530168
laurapang@honeybearbio.com